A comprehensive review on targeted therapies for triple negative breast cancer: an evidence-based treatment guideline

Funding Sponsor

Science and Technology Development Fund

Author's Department

Nanotechnology Program

Second Author's Department

Energy Materials Laboratory

Find in your Library

https://doi.org/10.1007/s12672-025-02227-6

All Authors

Hadir M. Emara Nageh K. Allam Rana A. Youness

Document Type

Research Article

Publication Title

Discover Oncology

Publication Date

12-1-2025

doi

10.1007/s12672-025-02227-6

Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by limited therapeutic options and poor prognosis. Despite advancements in precision oncology, conventional chemotherapy remains the cornerstone of TNBC treatment, often accompanied by debilitating side effects and suboptimal outcomes. This review presents a comprehensive analysis of clinical trials on targeted therapies, aiming to establish a novel, evidence-based treatment strategy exclusively leveraging molecularly targeted agents. By integrating patient-specific genetic profiles with therapeutic responses observed across various clinical trial phases, this approach seeks to optimize efficacy while minimizing toxicity. The proposed targeted therapy combinations hold significant potential to revolutionize TNBC treatment, offering a paradigm shift toward precision medicine and improved patient outcomes.

Link to Full Text
Find this item online

Share

COinS